And now it's up 4.5% I'm trying to ignore the tiny volume, and stay focused on the long-term vision, where $VLTLF $LIB builds out the commercial unit. Once that happens, all the short-term price swings driven by thin volume should fade & the real valuation will follow

On top $VLTLF $LIB is a US domestic producer & will have all the advantages as a US producer instead of relying on Chinese #lithium The suspension of Lithium mining by Chinese producer due to high cost of mining & refining, while $VLTLF is turning a waste product into lithium

The market is spiking after the CPI data $SPY is up >$639 $XBI is up > $86 $QQQ is up > $576 $VIX is down to $18.25 down over 6%

$CRDL's CEO highlighted that the Archer data provides a read-through to the Ph-3 trial in pericarditis, both conditions involve inflammation, which CardiolRx targets. The therapy shows potential as a disease-modifying treatment.

$EPRX The 3 patients from Cohort-5 demonstrated a sustained or improved treatment outcome after 9-months of therapy! Additional data from cohorts 5–8 from Ph-1b/2a available in October-2025

This slide explain well how $EPRX's Diffusphere technology works in steady-state diffusion of drug EP-104GI is engineered for targeted, sustained drug delivery to the esophageal wall, potentially enabling once-yearly dosing administered during routine endoscopy #EoE

This highlight the importance of $EPRX's once a year treatment! Effective & durable is the key Any #EoE patient who tried SoC treatment with steroids & have to discontinue after a 2 or 3 months due to side effect like candidiasis Next, Dupixent with weekly injection & endoscopy

$VLTLF $LIB critical minerals like #Lithium are well needed in the US! The department's Office of Manufacturing and Energy Supply Chains (MESC) intends to offer up to $500 million in funding to expand U.S. critical minerals and materials processing and battery manufacturing and

$CRDL recovering from the overreaction & drop post the #myocarditis data release! The reduction in left ventricular (LV) mass observed in the Ph-2 ARCHER trial is indeed significant and noteworthy, especially in the context of acute myocarditis!

Please retweet: A very important message to @XSupport & Elon Musk Bots and spam are ruining X search, making it unusable for loyal subscribers. Many are ready to leave & looking for alternative.... Please address this urgently! Why on earth, my search should looks like this:

The next gen with #AI is waiting for the FDA approval! The day it got approved $PYNKF $PINK will reach the inflection point they are waiting for & the street will understand the importance of this OCT device to be placed in every operation room! Watch youtu.be/RPBpDNCF0AQ?si…

$CNVIF $CNVI.v's CEO shares insights into Conavi’s product & trajectory, and advice on navigating challenges in #medtech operations and development. healthconnectivetech.com/show/overcomin…

$CLDX's EoE trial failure underscores $EPRX's unique MOA and success in #EoE, positioning it as a potential standard of care. Unlike therapies targeting IL-13, eosinophils, mast cells, or TSLP, steroids act upstream to address them all. Systemic steroids pose challenges, but

Advancing #EoE Treatment Amid Biologic Setbacks: $CLDX Failure Reinforces $EPRX's Edge chimeraresearchgroup.com/2025/08/advanc…

The #MedTech adoption is so important for any company to become a success story. And $CNVI.v $CNVIF with it's IVI- Intravascular Imaging hybrid device that combine #IVUS depth & #OCT precision in a single catheter, would be the first to take advantage in this $1B to $4B market

$CLDX's #EoE Ph-2 failure highlights the complexity of EoE, with multiple inflammatory pathways challenging systemic biologics, as seen in repeated mAb trial setbacks. $EPRX's localized Precision Delivery Platform with EP-104GI offers a promising, durable solution. #Biotech

#Lithium: By 2030, global supply is projected to fall short by millions of tonnes. That’s bullish for U.S.-based producer like $VLTLF $LIB, who is pioneering lithium extraction from oil & gas byproduct brine. #LibertyStream is in the process to scale its modular Gen-5

$CNVI.v $CNVIF Lancent publication: 22 randomized trials, demonstrate using imaging device like Conavi's Hybrid device, you can save the life of up to 46% of patients post procedure & save on blood clots by 52% #Intravascular #Imaging #coronary youtu.be/SG3zZJum8vI?si…

Yes, $CNVIF $CNVI.v hybrid IVUS+OCT is the future in coronary intravascular imaging! Philips focus is on IVUS systems like IntraSight and Eagle Eye Platinum catheters. Philips does not offer a standalone OCT intravascular imaging device or hybrid IVUS-OCT device like Conavi’s

The slow trading days & low volume through Jul–Aug are typical, as many investors take summer vacations I like the sideways action on $EPRX, with a clear "pennant formation" signaling price consolidation within a tight horizontal channel. Hint: Buyers are scooping up every dip